Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEP-4199 (Sumitomo Pharma)
- Development stage
- Discontinued
- Lead developer
- Sunovion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SEP-4199** is an investigational oral, controlled-release non-racemic amisulpride product comprising **aramisulpride** and **esamisulpride** in an 85:15 ratio. It was developed for major depressive episodes associated with bipolar I disorder. The enantiomeric ratio was selected to emphasize serotonin 5-HT7 receptor antagonism while limiting dopamine D2 receptor antagonism and D2 receptor occupancy relative to racemic amisulpride, with the aim of improving antidepressant activity and tolerability. Sumitomo Pharma-sponsored Phase 3 studies in bipolar I depression were terminated, and SEP-4199 was absent from Sumitomo Pharma's July 31, 2026 development pipeline. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8453756/))
- Other names
- non-racemic amisulpride
02
Targets
HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on SEP-4199 (Sumitomo Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEP-4199 (Sumitomo Pharma).